United Therapeutics Corp. (NASDAQ:UTHR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday. The firm currently has a $159.00 price objective on the biotechnology company’s stock. Zacks Investment Research’s target price points to a potential upside of 11.96% from the company’s previous close. […]
